Roswell, GA-based rare disease biotech developing therapies for pain, osteoarthritis, spasticity, and mitochondrial disorders, with a strategic focus on underserved CNS indications.
SL1009 NDA resubmission acknowledged by FDA
Expected FDA action on SL1009 NDA
Saol Therapeutics has completed patient enrollment in the pivotal Phase III BEACON trial of SL1002 in chronic pain associated with knee osteoarthritis.
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026.
Saol boards FDA’s resubmission boat, armed with new survival data (BioSpace.)
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease (reported by PR Newswire)
Chief Executive Officer